Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Venture Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 4.800
Day High 5.250
Open:4.900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products. Geographically all the activities are functioned through the region of Canada.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

BioSyent Releases Results for Q1 2020
- GlobeNewswire - Thu May 28, 7:00AM CDT
GlobeNewswire - CMTX
Thu May 28, 7:00AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key highlights include:
BioSyent Schedules Q1 2020 Earnings Release For May 28, 2020
- GlobeNewswire - Thu May 21, 7:00AM CDT
GlobeNewswire - CMTX
Thu May 21, 7:00AM CDT
BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on Thursday, May 28, 2020. A presentation on the Company's first quarter 2020 results by Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
FeraMAX(R) Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year
- GlobeNewswire - Fri May 1, 8:00AM CDT
GlobeNewswire - CMTX
Fri May 1, 8:00AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAXhas been named the #1 recommended iron supplement brand in a national survey of Canadian pharmacists and physicians.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 3.800 +26.32% increase
on 05/13/20
Period Open:4.340
Price movement based on the high, low and last over the given period.
5.250 -8.57% decrease
on 06/01/20
+0.460 (+10.60%) increase
since 05/01/20
3-Month 3.130 +53.35% increase
on 03/18/20
Period Open:5.100
Price movement based on the high, low and last over the given period.
5.250 -8.57% decrease
on 06/01/20
-0.300 (-5.88%) decrease
since 02/28/20
52-Week 3.130 +53.35% increase
on 03/18/20
Period Open:7.570
Price movement based on the high, low and last over the given period.
7.500 -36.00% decrease
on 07/23/19
-2.770 (-36.59%) decrease
since 05/31/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies